Cost and cost-effectiveness analysis of the preferred treatment for initial antiretroviral therapy in HIV infected adults according to 2012 GESIDA/National AIDS Plan guidelines
Betegón, L.; Cotarelo, M.; Vendrell, Bén.
Enfermedades infecciosas y microbiologia clinica 30(8): 508-9; author reply 511-2
2012
ISSN/ISBN: 0213-005X PMID: 22819541 DOI: 10.1016/j.eimc.2012.06.002Document Number: 276666
Document emailed within 0-6 h
Related Documents
Podzamczer, D.; Barros, C.; Berenguer, J.; Gutiérrez, Félix.; Iribarren, Jé.Antonio.; Miró, Jé.M.; Molina, Jé.Pérez.; Podzamczer, D.; Aguirrebengoa, K.; Arribas, Jé.Ramón.; Boix, V.; Cahn, P.; Castro, A.; Caylá, J.; Cobo, J.; Corzo, J.Enrique.; de la Torre, J.; Dronda, F.; Ena, J.; Falcó, Vç.; Ferrer, E.; Labarga, P.; Locutura, J.; Mallolas, J.; Moreno, S.; Ocampo, A.; Ocaña, Ján.; Padilla, Bén.; Elías, Jús.Pérez.; Polo, R.; Portilla, Jín.; Riera, M.; Rivero, A.; Salavert, M.; Sanz, Jé. 2008: Treatment of opportunistic infections in adolescent and adult patients infected with the human immunodeficiency virus during the era of highly active antiretroviral therapy. AIDS Study Group (GESIDA) and National AIDS Plan Expert Committee Enfermedades Infecciosas y Microbiologia Clinica 26(6): 356-379Koethe, J.R.; Marseille, E.; Giganti, M.J.; Chi, B.H.; Heimburger, D.; Stringer, J.S. 2014: Estimating the cost-effectiveness of nutrition supplementation for malnourished, HIV-infected adults starting antiretroviral therapy in a resource-constrained setting Cost Effectiveness and Resource Allocation: C/E 12: 10
Podzamczer, D.; Miralles, P.; La Calle Md, Mía.de.; Zarco, C.; Berenguer, J.; López Aldeguer, Jé.; Valencia, E.; Rubio, R.; Ribera, J-María. 2002: Recommendations of GESIDA/Spanish National Plan of AIDS on diagnosis and treatment of Kaposi's sarcoma and cervical cancer in HIV-infected patients Medicina Clinica 118(20): 788-795
Marseille, E.; Giganti, M.J.; Mwango, A.; Chisembele-Taylor, A.; Mulenga, L.; Over, M.; Kahn, J.G.; Stringer, J.S.A. 2012: Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia Plos one 7(12): E51993
Scott Braithwaite, R.; Nucifora, K.A.; Toohey, C.; Kessler, J.; Uhler, L.M.; Mentor, S.M.; Keebler, D.; Hallett, T. 2014: How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? Aids 28 Suppl. 1: S73-S83
Corzillius, M.; Mühlberger, N.; Sroczynski, G.; Jaeger, H.; Wasem, J.ür.; Siebert, U. 2004: Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV Antiviral Therapy 9(1): 27-36
Contreras-Hernandez, I.; Becker, D.; Chancellor, J.; Kühne, F.; Mould-Quevedo, J.; Vega, G.; Marfatia, S. 2010: Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 13(8): 903-914
Collins, I.J.; Cairns, J.; Ngo-Giang-Huong, N.; Sirirungsi, W.; Leechanachai, P.; Le Coeur, S.; Samleerat, T.; Kamonpakorn, N.; Mekmullica, J.; Jourdain, G.; Lallemant, M. 2014: Cost-effectiveness of early infant HIV diagnosis of HIV-exposed infants and immediate antiretroviral therapy in HIV-infected children under 24 months in Thailand Plos one 9(3): E91004
Eaton, J.W.; Menzies, N.A.; Stover, J.; Cambiano, V.; Chindelevitch, L.; Cori, A.; Hontelez, J.A.C.; Humair, S.; Kerr, C.C.; Klein, D.J.; Mishra, S.; Mitchell, K.M.; Nichols, B.E.; Vickerman, P.; Bakker, R.; Bärnighausen, T.; Bershteyn, A.; Bloom, D.E.; Boily, M-Claude.; Chang, S.T.; Cohen, T.; Dodd, P.J.; Fraser, C.; Gopalappa, C.; Lundgren, J.; Martin, N.K.; Mikkelsen, E.; Mountain, E.; Pham, Q.D.; Pickles, M.; Phillips, A.; Platt, L.; Pretorius, C.; Prudden, H.J.; Salomon, J.A.; van de Vijver, D.A.M.C.; de Vlas, S.J.; Wagner, B.G.; White, R.G.; Wilson, D.P 2014: Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models Lancet. Global health 2(1): e23-e34
Pinto, J.L.; López Lavid, C.; Badia, X.; Coma, A.; Benavides, A. 2000: Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients Medicina Clinica 114(Suppl 3): 62-67
Sungkanuparph, S.; Anekthananon, T.; Hiransuthikul, N.; Bowonwatanuwong, C.; Supparatpinyo, K.; Mootsikapun, P.; Chetchotisakd, P.; Kiertiburanakul, S.; Tansuphaswadikul, S.; Buppanharun, W.; Manosuthi, W.; Techasathit, W.; Ratanasuwan, W.; Tantisiriwat, W.; Suwanagool, S.; Leechawengwongs, M.; Ruxrungtham, K. 2008: Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008 Journal of the Medical Association of Thailand 91(12): 1925-1935
Rodrigues, R.; Bogg, L.; Shet, A.; Kumar, D.Sunil.; De Costa, A. 2014: Mobile phones to support adherence to antiretroviral therapy: what would it cost the Indian National AIDS Control Programme? Journal of the International Aids Society 17: 19036
Pho, M.T.; Swaminathan, S.; Kumarasamy, N.; Losina, E.; Ponnuraja, C.; Uhler, L.M.; Scott, C.A.; Mayer, K.H.; Freedberg, K.A.; Walensky, R.P. 2012: The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis Plos one 7(4): E36001
Ouattara, E.N.; Ross, E.L.; Yazdanpanah, Y.; Wong, A.Y.; Robine, M.; Losina, E.; Moh, R.; Walensky, R.P.; Danel, C.; Paltiel, A.D.; Eholié, S.P.; Freedberg, K.A.; Anglaret, X. 2014: Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire Journal of Acquired Immune Deficiency Syndromes 66(3): 294-302
Alistar, S.S.; Grant, P.M.; Bendavid, E. 2014: Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa Bmc Medicine 12: 46
Mielck, A. 1988: Cost-effectiveness and cost-benefit approaches in programs designed to prevent AIDS Aids and Public Policy Journal 3(3): 19-22
Polo Rodríguez, R.; Amador Prous, Cón.; Deig Comerma, E.; Fumaz, C.R.; Galindo Puerto, M.José.; Koerting de Castro, A.; Merino Munoz, D.; Miralles Álvarez, C.; MunozGálligo, E.; Núnez Cuadros, E.; Ollé Rodríguez, C.; Pérez Elías, M.Jesús.; Valencia Ortega, E.; Gisbert Civera, I. 2014: Executive summary of the consensus statement on assistance to women with HIV infection in the health care sector. National AIDS Plan (PNS) and AIDS Study Group (GeSIDA) Enfermedades infecciosas y microbiologia clinica 32(2): 100-105
Polo Rodríguez, R.; Amador Prous, Cón.; Deig Comerma, E.; Fumaz, C.R.; Galindo Puerto, M.José.; Koerting de Castro, A.; Merino Munoz, D.; Miralles Álvarez, C.; MunozGálligo, E.; Núnez Cuadros, E.; Ollé Rodríguez, C.; Pérez Elías, M.Jesús.; Valencia Ortega, E.; Gisbert Civera, I. 2014: Executive summary of the consensus statement on assistance to women with HIV infection in the health care sector. National AIDS Plan (PNS) and AIDS Study Group (GeSIDA) Enfermedades infecciosas y microbiologia clinica 32(2): 100-105
Walker, D. 2003: Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base? Health Policy and Planning 18(1): 4-17
Carvalho, N.; Salehi, A.Shah.; Goldie, S.J. 2013: National and sub-national analysis of the health benefits and cost-effectiveness of strategies to reduce maternal mortality in Afghanistan Health Policy and Planning 28(1): 62-74